Clearfield Capital Management’s Bio-Rad Laboratories Class A BIO Stock Holding History

Clearfield Capital Management’s Portfolio BIO Stock Details BIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-50,771	Closed	-$14.6M	–	15
2018 Q2	$14.6M	Sell	50,771 -67,268	-57%	-$18.6M	3.71%	12
2018 Q1	$29.5M	Sell	118,039 -1,823	-2%	-$464K	7.65%	5
2017 Q4	$28.6M	Sell	119,862 -75,613	-39%	-$18.3M	5.34%	11
2017 Q3	$43.4M	Sell	195,475 -7,028	-3%	-$1.58M	8.15%	4
2017 Q2	$45.8M	Buy	+202,503	New	+$44.1M	7.48%	3

Other funds holding BIO

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ACM

Atlanta Capital Management Atlanta, Georgia $22.5B AUM 9.67% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

TCM

TimesSquare Capital Management New York $5.89B AUM 28.74% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

Clearfield Capital Management's BIO Position: Q3 2018 in Review

Clearfield Capital Management sold out of Bio-Rad Laboratories Class A (BIO) in Q3 2018, closing a stake of 50,771 shares — an estimated $14.6M sold.

Clearfield Capital Management first reported a position in BIO in Q2 2017 and held it in 5 quarters. The position peaked at $45.8M in Q2 2017. 344 funds tracked by Wall St. Rank hold BIO as of Q3 2018.

Clearfield Capital Management reported no remaining Bio-Rad Laboratories Class A position as of Q3 2018 after selling out during the quarter.
Clearfield Capital Management sold 50,771 Bio-Rad Laboratories Class A shares in Q3 2018, an estimated $14.6M.
Clearfield Capital Management first reported a position in Bio-Rad Laboratories Class A in Q2 2017 and held it in 5 quarters.
Clearfield Capital Management's Bio-Rad Laboratories Class A position peaked at $45.8M in Q2 2017.
344 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q3 2018.

Based on Clearfield Capital Management's 13F filing for Q3 2018, filed 14 Nov 2018.